SNAP40 Study
Start date:September 2017 End date:
December 2017 Co-ordinated by:
EMERGE Main trial site:
Royal Infirmary of Edinburgh
SNAP40-ED: Detection of physiological deterioration by the SNAP40 wearable device compared to standard monitoring devices in the Emergency Department.
SNAP40 is a device that monitors vital signs. It is small, portable and has no leads or wires, allowing for patients vital signs to be continuously monitored anywhere in the department. The device is smaller than most mobile phones, and is held within a blue casing attached to an armband (please see image). When fitted to a patient’s arm, the device will continuously monitor their vital signs whilst they are in the Emergency Department.
SNAP40 uses artificial intelligence algorithms to analyse data provided by its sensors in order to recognise indicators of health deterioration. The raw data collected by the sensors is converted into vital signs, which are analysed for signs of deterioration. An alert will be sent to staff if the device detects any signs of deterioration in the patient’s readings.
Funding: SNAP40
Sponsor: SNAP40, Forth Street, Edinburgh (UK)
Setting: This is a single centre study being co-ordinated from Edinburgh.
Chief Investigator
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
Research Team
Rachel O'Brien
Lead Research Nurse
Polly Black
Senior Research Nurse
Alison Grant
Senior Research Nurse
Mary Morrissey
Senior Research Nurse
Related news
Exciting new trial: SNAP40
10 Apr 2017 | Megan McGrath
EMERGE will soon begin recruitment to the new SNAP40 trial which will compare the new SNAP40 device with standard monitoring devices in the Emergency Department.
Read moreMore EMERGE Trials
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.
KRAKIL Study
ATTEST2 Trial
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
IONA Study
Identification of Novel Psychoactive Substances (IONA)